Adma Biologics Stock Price, News & Analysis

ADMA Biologics (Nasdaq: ADMA) has scheduled its fourth quarter and full year 2024 financial results announcement for March 3, 2025, after U.S. financial markets close. The company's management team will host a conference call and audio webcast at 4:30 p.m. ET on the same day to discuss financial results and provide company updates.

Interested participants can access the conference call by dialing (888) 596-4144 with conference ID 5201334. It's recommended to join approximately 10 minutes before the event starts. Those not planning to ask questions are encouraged to listen to the live webcast available on the company's website. An archived replay will be available in the investor section under "Events & Webcasts" at ir.admabiologics.com/events-webcasts.

ADMA Biologics is an end-to-end commercial biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics.

ADMA Biologics has announced its preliminary unaudited revenue for FY 2024, estimating a total revenue of approximately $417-425 million, exceeding its previous guidance of $415 million. The company's total cash holdings at year-end 2024 grew to more than $100 million, a $45 million increase quarter-over-quarter, despite organically discharging $30 million of debt during Q4 2024.

Newly executed high-titer plasma supply contracts are expected to support durable revenue growth for ASCENIV through the late 2030s. Additionally, ADMA has submitted a PAS to the FDA for approval of an innovative yield enhancement production process, with potential regulatory approval anticipated by mid-2025.

The company has provided revenue guidance for FY 2025 and 2026, expecting to exceed $485 million and $600 million, respectively. Net income for these years is projected to surpass $170 million and $230 million, while adjusted EBITDA is expected to exceed $220 million and $300 million, respectively. ADMA aims to generate over $1 billion in total annual revenue before 2030, more than doubling the current 2025 revenue forecast.

ADMA Biologics (Nasdaq: ADMA) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. The company's presentation is scheduled for Monday, January 13, 2025, at 10:30 a.m. PT.

As an end-to-end commercial biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics, ADMA will make its presentation available through a live audio webcast accessible via the investor section of the company's website under 'Events & Webcasts'. An archived version of the webcast will be available approximately two hours after the event.

ADMA Biologics announced a $30 million partial paydown of its senior secured term loan facility with Ares Capital, using cash on hand. This represents the second paydown in four months, reducing the company's total gross debt by 29% to $75 million. The remaining debt consists of a $42.5 million revolving credit facility and $32.5 million outstanding under the term loan facility.

The company attributes this debt reduction to organically generated cash flow, and management expects the lowered interest expense to enhance earnings growth potential in upcoming periods. ADMA plans to continue optimizing its cost of both debt and equity capital moving forward.

ADMA Biologics reported outstanding third quarter 2024 results with total revenue of $119.8 million, up 78% year-over-year. The company achieved GAAP Net Income of $35.9 million, a 1,300% increase, and Adjusted EBITDA of $45.4 million, up 256%. Gross profits reached $59.7 million with a 50% margin. ADMA increased its guidance for FY 2024, expecting revenue over $415 million and GAAP net income exceeding $120 million. The company's higher-margin product ASCENIV now accounts for over 50% of total revenue. ADMA also joined the S&P SmallCap 600 Index and appointed KPMG LLP as its new independent auditor.

ADMA Biologics (Nasdaq: ADMA) has announced it will report its third quarter 2024 financial results on November 7, 2024, after U.S. market close. The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day. Participants can dial (888) 596-4144 with conference ID 2959956 to join the call. A webcast will be available for those not asking questions, and an archived replay will be accessible through the company's investor relations website.

ADMA Biologics (Nasdaq: ADMA), a biopharmaceutical company specializing in specialty biologics, has announced its inclusion in the S&P SmallCap 600 index, effective September 23, 2024. This milestone is expected to increase ADMA's visibility among investors and enhance share liquidity. The S&P SmallCap 600 index, designed to measure the small-cap segment of the U.S. equity market, comprises 600 companies meeting specific criteria for liquidity and financial viability.

Adam Grossman, ADMA's President and CEO, emphasized the significance of this inclusion as the company continues to execute its growth strategy. The move reflects ADMA's progress and potential in the biopharmaceutical sector, particularly in manufacturing, marketing, and developing specialty biologics.

ADMA Biologics, Inc. (Nasdaq: ADMA), a commercial biopharmaceutical company focused on specialty biologics, has announced its participation in the 2024 Cantor Global Healthcare Conference. The event will take place in New York, NY on September 17, 2024.

Key details:

• Adam Grossman, President and CEO, will participate in a fireside chat
• The presentation is scheduled for 3:05 p.m. ET
• A live audio webcast will be available on the company's investor relations website
• An archived version of the webcast will be accessible approximately two hours after the event

This conference provides ADMA Biologics with an opportunity to showcase its progress and strategy to investors and industry professionals in the healthcare sector.

ADMA Biologics has announced a partial paydown of its revolving credit facility, utilizing $30 million of cash on hand to repay Ares Capital. This move reduces ADMA's total debt to $105 million, a 22% reduction from its previous level. The company's debt now consists of a $62.5 million term loan and $42.5 million outstanding under the revolving credit facility. ADMA's President and CEO, Adam Grossman, stated that this decision reflects the company's confidence in sustained earnings growth and anticipated ongoing cash generation. The reduced interest expense is expected to enhance earnings growth potential in the near future. ADMA plans to further optimize its cost of both debt and equity capital moving forward.